Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

Dear Dr. Roach: I am a 53-year-old healthy male, and I always request to check my PSA levels each year. My 57-year-old brother's new doctor denied his request for a routine PSA check on their initial ...

Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...

Mass population testing for prostate cancer will not see men proactively invited for the PSA blood test - here is all you need to know about who can get checked ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

Professor Freddie Hamdy - who advised the Government not to offer more men the PSA blood test - explains why very slow growing tumours should be left well alone ...

Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...